28 research outputs found
Effect of δ-opioid receptor activation on BDNF-TrkB vs. TNF-α in the mouse cortex exposed to prolonged hypoxia.
We investigated whether
δ
-opioid receptor (DOR)-induced neuroprotection
involves the brain-derived neur
otrophic factor (BDNF) pathway.
We studied the effect of
DOR activation on the expression
of BDNF and other proteins
in the cortex of C57BL/6
mice exposed to hypoxia (10% of oxygen) for 1–10
days. The results showed that: (1) 1-day
hypoxia had no appreciable eff
ect on BDNF expression, wh
ile 3- and 10-day hypoxia
progressively decreased BDNF expression, resulting in 37.3% reduction (
p <
0.05) after
10-day exposure; (2) DOR activa
tion with UFP-512 (1 mg/kg, i
.p., daily) partially reversed
the hypoxia-induced reductio
n of BDNF expression in the
3- or 10-day exposed cortex;
(3) DOR activation partially reversed the
hypoxia-induced reduction in functional TrkB
(140-kDa) and attenuated hypoxia-indu
ced increase in truncated Tr
kB (90-kDa) in the 3- or
10-day hypoxic cortex; and (4) prolonged hypoxi
a (10 days) significantly increased TNF-
α
level and decreased CD11b expression in the cortex, which was completely reversed
following DOR activation; and (5) there was
no significant change in pCREB and pATF-1
levels in the hypoxic cortex. We concl
ude that prolonged hypoxia down-regulates BDNF-TrkB signaling leading to an increase in TNF-α in the cortex, while DOR activation
up-regulates BDNF-TrkB signaling thereby decreasing TNF-α levels in the hypoxic cortex
Efficacy of Antibiotic-Impregnated Bone Cement Beads Against Organisms Found in Abdominal Vascular Graft Infections
Risk Factors and Outcomes of Acute and Chronic Type B Aortic Dissection Versus Descending Thoracic Aneurysm From the Global Registry for Endovascular Aortic Treatment
Impact of Gender on Treatment of Carotid-Artery Stenosis: A Secondary Data Analysis on Space Trial
Endovascular treatment of complicated versus uncomplicated acute type B aortic dissection
Objective: The study objective was to analyze the outcomes of thoracic endovascular aortic repair performed for complicated and uncomplicated acute type B aortic dissections. Methods: Patients from WL Gore's Global Registry for Endovascular Aortic Treatment who underwent thoracic endovascular aortic repair for acute type B aortic dissections were included, and data were retrospectively analyzed. Results: Of 5014 patients enrolled in the Global Registry for Endovascular Aortic Treatment, 172 underwent thoracic endovascular aortic repair for acute type B aortic dissections. Of these repairs, 102 were for complicated acute type B aortic dissections and 70 were for uncomplicated acute type B aortic dissections. There were 46 (45.1%) procedures related to aortic branch vessels versus 15 (21.4%) in complicated type B aortic dissections and uncomplicated type B aortic dissections (P = .002). The mean length of stay was 14.3 ± 10.6 days (median, 11; range, 2-75) versus 9.8 ± 7.9 days (median, 8; range, 0-42) in those with complicated type B aortic dissections versus those with uncomplicated acute type B aortic dissections (P < .001). Thirty-day mortality was not different between groups (complicated type B aortic dissections 2.9% vs uncomplicated acute type B aortic dissections 1.4%, P = .647), as well as aortic complications (8.8% vs 5.7%, P = .449). Aortic event-free survival was 62.9% ± 37.1% versus 70.6% ± 29.3% at 3 years (P = .696). Conclusions: In the Global Registry for Endovascular Aortic Treatment, thoracic endovascular aortic repair results for complicated type B aortic dissections versus uncomplicated acute type B aortic dissections showed that 30-day mortality and perioperative complications were equally low for both. The midterm outcome was positive. These data confirm that thoracic endovascular aortic repair as the first-line strategy for treating complicated type B dissections is associated with a low risk of complications. Further studies with longer follow-up are necessary to define the role of thoracic endovascular aortic repair in uncomplicated acute type B dissections compared with medical therapy. However, in the absence of level A evidence from randomized trials, results of the uncomplicated acute type B aortic dissection patient cohort treated with thoracic endovascular aortic repair from registries are important to understand the related risk and benefit